Liver failure is the end stage of hepatopathy with unfavorable prognosis.In two patients with liver failure,viable primary human hepatocytes,obtained from resected liver tissue of patients with hepatolithiasis.were tr...Liver failure is the end stage of hepatopathy with unfavorable prognosis.In two patients with liver failure,viable primary human hepatocytes,obtained from resected liver tissue of patients with hepatolithiasis.were transplanted into the spleen by interventional therapy through femoral arterial cannula.After transplantation,the patients’ clinical symptoms and liver function were significantly improved.However,their bilirubin increased within six days following transplantation.One suffered from hepatic coma and give up treatment and the other patient died forteen days after transplantation.It is technically safe to treat liver failure by intrasplenic transplantation of adult hepatocytes and the clinical efficacy has been confirmed.How to make transplanted hepatic cells proliferate and functionally survive is the key point to maintain continuous improvement of the recipient’s hepatic function.展开更多
The shortage of organ donors is a problem worldwide, with approximately 15% of adult patients with lifethreatening liver diseases dying while on the waiting list. The use of cell transplantation for liver disease is a...The shortage of organ donors is a problem worldwide, with approximately 15% of adult patients with lifethreatening liver diseases dying while on the waiting list. The use of cell transplantation for liver disease is an attempt to correct metabolic defects, or to support liver function as a bridge to liver transplantation and, as such, has raised a number of expectations. Most of the available studies briefly reported here focus on adult hepatocyte transplantation (HT), and the results are neither reproducible nor comparable, because the means of infusion, amount of injected cells and clinical variability differ among the studies. To better understand the specif ic role of HT in the management of end-stage liver disease, it is important that controlled studies, designed on the principles of evidence-based medicine, be done in order to guarantee the reproducibility of results.展开更多
Background Mostly because of the limited number and proliferative ability of the transplanted hepatocytes, hepatocyte transplantation offers only temporary support to the hepatic function with rather poor functional r...Background Mostly because of the limited number and proliferative ability of the transplanted hepatocytes, hepatocyte transplantation offers only temporary support to the hepatic function with rather poor functional replacement of the damaged liver parenchyma. This study aimed to observe the therapeutic effect of human thioredoxin （hTrx） gene-modified hepatocytes on experimental acute liver failure in rats. Methods hTrx cDNA was obtained by reverse transcription-polymerase chain reaction （RT-PCR） from human osteosarcoma 143 （TK-） cells to construct the recombinant retrovirus vector pLEGFP/hTrx, which was packaged into PA317 cells to collect the recombinant retrovirus containing hTrx gene. After titration and characterization, the recombinant retrovirus was applied to primary cultured rat hepatocyte for infection to generate hTrx gene-modified rat hepatocytes, whose viability and antioxidative capacity were examined by immunohistochemistry and MTT assay, respectively. In a Sprague-Dawley （SD） rat model of acute liver failure, the modified hepatocytes were injected into the spleen, and the hepatic function and survival rate of the recipient rats were evaluated at different time points after the transplantation. Results NIH3T3 cells infected by the recombinant retrovirus were capable of expressing bioactive hTrx in the form of fusion proteins. Immunohistochemistry demonstrated normal function of the hTrx gene-modified hepatocytes, which possessed strong antioxidative capacity as shown by MTT assay. Transplantation of the modified hepatocytes in rats with acute liver failure resulted in significantly lowered serum alanine aminotransferase （ALT） and total bilirubin （TBIL） levels （P 〈0.05）. The hepatocytes exhibited long-term survival and efficient proliferation after transplantation. Fourteen days after the operation, the rat models receiving hTrx gene-modified hepatocytes had significantly higher survival rate than those without the transplantation. Conclusion hTrx gene-modified hepatocyte transplantation can effectively alleviate acute liver failure in rats.展开更多
Liver disease has long been a heavy health and economic burden worldwide.Once the disease is out of control and progresses to end-stage or acute organ failure,orthotopic liver transplantation(OLT)is the only therapeut...Liver disease has long been a heavy health and economic burden worldwide.Once the disease is out of control and progresses to end-stage or acute organ failure,orthotopic liver transplantation(OLT)is the only therapeutic alternative,and it requires appropriate donors and aggressive administration of immunosuppressive drugs.Therefore,hepatocyte transplantation(HT)and bioartificial livers(BALs)have been proposed as effective treatments for acute liver failure(ALF)in clinics.Although human primary hepatocytes(PHs)are an ideal cell source to support these methods,the large demand and superior viability of PH is needed,which restrains its wide usage.Thus,a finding alternative to meet the quantity and quality of hepatocytes is urgent.In this context,human pluripotent stem cells(PSC),which have unlimited proliferative and differential potential,derived hepatocytes are a promising renewable cell source.Recent studies of the differentiation of PSC into hepatocytes has provided evidence that supports their clinical application.In this review,we discuss the recent status and future directions of the potential use of PSC-derived hepatocytes in treating ALF.We also discuss opportunities and challenges of how to promote such strategies in the common applications in clinical treatments.展开更多
目的探讨同种异体肝细胞腹腔移植联合肝再生增强因子(augmenter of liver regenration,ALR)对D-氨基半乳糖(D-gal)诱导的急性肝功能衰竭大鼠的治疗作用。方法采用D-gal诱导大鼠急性肝功能衰竭,诱导后24h,59只大鼠随机数字表法分成4组。...目的探讨同种异体肝细胞腹腔移植联合肝再生增强因子(augmenter of liver regenration,ALR)对D-氨基半乳糖(D-gal)诱导的急性肝功能衰竭大鼠的治疗作用。方法采用D-gal诱导大鼠急性肝功能衰竭,诱导后24h,59只大鼠随机数字表法分成4组。Ⅰ组15只:腹腔注射生理盐水;Ⅱ组15只:经腹腔移植2×107肝细胞,以后腹腔注射生理盐水;Ⅲ组15只:经腹腔移植2×107肝细胞,同时腹腔注射ALR50μg.kg-1.d-1;Ⅳ组14只:腹腔注射ALR50μg.kg-1.d-1。观察大鼠的存活率、肝脏功能、移植肝细胞存活情况、病理变化。结果Ⅱ组、Ⅲ组大鼠存活率(46.7%、66.7%)显著高于Ⅰ组(0.0%)(P=0.006;P=0.0002),Ⅲ组(66.7%)与Ⅳ组(14.3%)有显著差异(P=0.008),其他组间无明显差异(P>0.05)。移植后第1、2天Ⅱ组腹水AST高于Ⅲ组(P=0.001),Ⅱ组第1、2天腹水ALT高于Ⅳ组,Ⅱ组、Ⅲ组第1、2天腹水TBil高于Ⅰ组(P<0.05)。Ⅲ组肝脏病理改变轻于其他组。Ⅲ组大鼠腹腔移植的肝细胞存活数多于Ⅱ组。结论同种异体肝细胞经腹腔移植联合ALR可明显改善D-gal诱导的肝衰竭大鼠的存活率,促进移植肝细胞存活和增殖,促进肝组织及功能恢复。展开更多
文摘Liver failure is the end stage of hepatopathy with unfavorable prognosis.In two patients with liver failure,viable primary human hepatocytes,obtained from resected liver tissue of patients with hepatolithiasis.were transplanted into the spleen by interventional therapy through femoral arterial cannula.After transplantation,the patients’ clinical symptoms and liver function were significantly improved.However,their bilirubin increased within six days following transplantation.One suffered from hepatic coma and give up treatment and the other patient died forteen days after transplantation.It is technically safe to treat liver failure by intrasplenic transplantation of adult hepatocytes and the clinical efficacy has been confirmed.How to make transplanted hepatic cells proliferate and functionally survive is the key point to maintain continuous improvement of the recipient’s hepatic function.
文摘The shortage of organ donors is a problem worldwide, with approximately 15% of adult patients with lifethreatening liver diseases dying while on the waiting list. The use of cell transplantation for liver disease is an attempt to correct metabolic defects, or to support liver function as a bridge to liver transplantation and, as such, has raised a number of expectations. Most of the available studies briefly reported here focus on adult hepatocyte transplantation (HT), and the results are neither reproducible nor comparable, because the means of infusion, amount of injected cells and clinical variability differ among the studies. To better understand the specif ic role of HT in the management of end-stage liver disease, it is important that controlled studies, designed on the principles of evidence-based medicine, be done in order to guarantee the reproducibility of results.
基金The study was supported by grants from the Major State Basic Research Development Program （973 Program） of China （No. 2009CB522404） and the National Natural Science Foundation of China （No. 30772135）.
文摘Background Mostly because of the limited number and proliferative ability of the transplanted hepatocytes, hepatocyte transplantation offers only temporary support to the hepatic function with rather poor functional replacement of the damaged liver parenchyma. This study aimed to observe the therapeutic effect of human thioredoxin （hTrx） gene-modified hepatocytes on experimental acute liver failure in rats. Methods hTrx cDNA was obtained by reverse transcription-polymerase chain reaction （RT-PCR） from human osteosarcoma 143 （TK-） cells to construct the recombinant retrovirus vector pLEGFP/hTrx, which was packaged into PA317 cells to collect the recombinant retrovirus containing hTrx gene. After titration and characterization, the recombinant retrovirus was applied to primary cultured rat hepatocyte for infection to generate hTrx gene-modified rat hepatocytes, whose viability and antioxidative capacity were examined by immunohistochemistry and MTT assay, respectively. In a Sprague-Dawley （SD） rat model of acute liver failure, the modified hepatocytes were injected into the spleen, and the hepatic function and survival rate of the recipient rats were evaluated at different time points after the transplantation. Results NIH3T3 cells infected by the recombinant retrovirus were capable of expressing bioactive hTrx in the form of fusion proteins. Immunohistochemistry demonstrated normal function of the hTrx gene-modified hepatocytes, which possessed strong antioxidative capacity as shown by MTT assay. Transplantation of the modified hepatocytes in rats with acute liver failure resulted in significantly lowered serum alanine aminotransferase （ALT） and total bilirubin （TBIL） levels （P 〈0.05）. The hepatocytes exhibited long-term survival and efficient proliferation after transplantation. Fourteen days after the operation, the rat models receiving hTrx gene-modified hepatocytes had significantly higher survival rate than those without the transplantation. Conclusion hTrx gene-modified hepatocyte transplantation can effectively alleviate acute liver failure in rats.
基金This research was supported by Shenzhen Key Laboratory of Inflammatory and Immunology Diseases(No.ZDSYS 20200811143756018)China Postdoctoral Science Foundation(No.2021M693290)+1 种基金the Key Program for Basic Research of Shenzhen Science and Technology Innovation Commission(No.JCYJ20200109140203849)Guangdong Basic and Applied Basic Research Foundation(No.2021A1515111000).
文摘Liver disease has long been a heavy health and economic burden worldwide.Once the disease is out of control and progresses to end-stage or acute organ failure,orthotopic liver transplantation(OLT)is the only therapeutic alternative,and it requires appropriate donors and aggressive administration of immunosuppressive drugs.Therefore,hepatocyte transplantation(HT)and bioartificial livers(BALs)have been proposed as effective treatments for acute liver failure(ALF)in clinics.Although human primary hepatocytes(PHs)are an ideal cell source to support these methods,the large demand and superior viability of PH is needed,which restrains its wide usage.Thus,a finding alternative to meet the quantity and quality of hepatocytes is urgent.In this context,human pluripotent stem cells(PSC),which have unlimited proliferative and differential potential,derived hepatocytes are a promising renewable cell source.Recent studies of the differentiation of PSC into hepatocytes has provided evidence that supports their clinical application.In this review,we discuss the recent status and future directions of the potential use of PSC-derived hepatocytes in treating ALF.We also discuss opportunities and challenges of how to promote such strategies in the common applications in clinical treatments.
文摘目的探讨同种异体肝细胞腹腔移植联合肝再生增强因子(augmenter of liver regenration,ALR)对D-氨基半乳糖(D-gal)诱导的急性肝功能衰竭大鼠的治疗作用。方法采用D-gal诱导大鼠急性肝功能衰竭,诱导后24h,59只大鼠随机数字表法分成4组。Ⅰ组15只:腹腔注射生理盐水;Ⅱ组15只:经腹腔移植2×107肝细胞,以后腹腔注射生理盐水;Ⅲ组15只:经腹腔移植2×107肝细胞,同时腹腔注射ALR50μg.kg-1.d-1;Ⅳ组14只:腹腔注射ALR50μg.kg-1.d-1。观察大鼠的存活率、肝脏功能、移植肝细胞存活情况、病理变化。结果Ⅱ组、Ⅲ组大鼠存活率(46.7%、66.7%)显著高于Ⅰ组(0.0%)(P=0.006;P=0.0002),Ⅲ组(66.7%)与Ⅳ组(14.3%)有显著差异(P=0.008),其他组间无明显差异(P>0.05)。移植后第1、2天Ⅱ组腹水AST高于Ⅲ组(P=0.001),Ⅱ组第1、2天腹水ALT高于Ⅳ组,Ⅱ组、Ⅲ组第1、2天腹水TBil高于Ⅰ组(P<0.05)。Ⅲ组肝脏病理改变轻于其他组。Ⅲ组大鼠腹腔移植的肝细胞存活数多于Ⅱ组。结论同种异体肝细胞经腹腔移植联合ALR可明显改善D-gal诱导的肝衰竭大鼠的存活率,促进移植肝细胞存活和增殖,促进肝组织及功能恢复。
文摘目的探索大鼠海藻酸钠-聚赖氨酸-海藻酸钠(APA)微囊小肝细胞样前体细胞(SHPC)移植治疗急性肝衰竭(AHF)大鼠模型的可行性和有效性。方法选择体质量150~180 g健康雄性Wistar大鼠10只。采用Retrosine(30 mg/kg)腹腔内注射联合2/3肝切除诱导雄性Wistar大鼠SHPC增殖模型,改进Seglen胶原酶灌注联合Percoll密度梯度离心分离SHPC,倒置显微镜、电子显微镜下观察,并进行免疫组织化学染色;静电液滴法APA微囊包埋。选择体质量180~220 g健康雌性Wistar大鼠20只,随机分为A组(微囊化SHPC腹腔内移植)、B组(空囊对照组);采用D-氨基半乳糖腹腔注射制备大鼠AHF模型;观察模型一般状况及生存时间,术后不同时间点检测血清丙氨酸转氨酶(ALT)、天门冬氨酸氨基转移酶(AST)、总胆红素(TBiL)及血氨水平,检测肝脏病理改变。结果Retrosine腹腔内注射联合2/3肝切除成功建立SHPC增殖模型,分离获得细胞符合大鼠SHPC;APA微囊呈光滑规则球形,直径为(300±40)μm,强度、韧性良好,囊内细胞形态完整,存活率为(90.0±1.3)%。微囊SHPC移植后,A组较B组中位生存时间延长(119.00 h vs 70.33 h),差异有统计学意义(P<0.05);随时间延长,A组大鼠血清ALT、AST、TBiL及血氨水平明显下降,均低于移植前水平,各时间点A组明显低于B组,差异有统计学意义(P<0.05);肝组织病理显示A组肝细胞损伤较B组明显改善;存活48 h大鼠腹腔内微囊保持完整光滑球形,囊内SHPC形态完整,1周微囊有散在破损皱缩,囊内细胞有增多聚集趋势,细胞存活率85%以上。结论APA微囊化大鼠SHPC腹腔内移植能改善大鼠AHF模型生存时间、生物化学指标(ALT、TBiL等)及病理损伤。
